INTRODUCTION TO THE
SANOFI PASTEUR
FLU VACCINE PORTFOLIO
2020-2021

Please click to see full Important Safety Information. Please click to see full Prescribing Information for Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent.
PROVEN TO PROVIDE SUPERIOR PROTECTION
compared to Fluzone® (Influenza Vaccine)\textsuperscript{1,2}

The efficacy of Fluzone High-Dose (trivalent formulation) is relevant to Fluzone High-Dose Quadrivalent since both vaccines are manufactured according to the same process and have overlapping compositions.\textsuperscript{1}

### KEY PRODUCT ATTRIBUTES

- Helps to protect against 2 influenza A strains and BOTH INFLUENZA B LINEAGES that co-circulate unpredictably each season\textsuperscript{1}
- 4X the amount of antigen of standard-dose quadrivalent inactivated influenza vaccine\textsuperscript{3}
- Similar safety profile compared to trivalent formulations of Fluzone High-Dose\textsuperscript{1}
- Covered by Medicare Part B and by most Medicare Advantage Plans with no copay
- Acquisition and administration fees are covered under Medicare Part B with no copay or deductible

### ACCORDING TO RESULTS FROM A RANDOMIZED CONTROLLED TRIAL PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE:

<table>
<thead>
<tr>
<th>PRIMARY ENDPOINT</th>
<th>SECONDARY ENDPOINT</th>
</tr>
</thead>
<tbody>
<tr>
<td>24% BETTER PROTECTION FROM INFLUENZA due to any strain\textsuperscript{1,2}</td>
<td>51% BETTER PROTECTION FROM INFLUENZA due to strains antigenically similar to those contained in the vaccine\textsuperscript{1,2}</td>
</tr>
</tbody>
</table>

**Primary Endpoint Definition:** the occurrence of laboratory-confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to vaccine components.\textsuperscript{1,2}

**Secondary Endpoint Definition:** the occurrence of culture-confirmed influenza caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations in association with a modified Centers for Disease Control and Prevention–defined influenza-like illness.\textsuperscript{1,2}

### SAFETY IN ADULTS 65+

Based on data from Fluzone High-Dose, solicited injection site reactions and systemic adverse reactions were slightly more frequent after vaccination with Fluzone High-Dose compared to a standard-dose vaccine.\textsuperscript{1}

Fluzone High-Dose Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.

### SELECT IMPORTANT SAFETY INFORMATION

Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine.

Please click to see full Important Safety Information.

Please click to see full Prescribing Information for Fluzone High-Dose Quadrivalent.

PRODUCT SNAPSHOT

NATIONAL DRUG CODE
- Carton (49281-0120-65)¹
- Unit (49281-0120-88)¹

CPT CODE
- 90662²

PRODUCT PRESENTATION
- Single-dose, 0.7-mL prefilled syringe³
- 10 syringes per carton²
- For intramuscular injection only²

SELECT IMPORTANT SAFETY INFORMATION
If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

Please click to see full Important Safety Information.
Please click to see full Prescribing Information for Fluzone High-Dose Quadrivalent.

KEY PRODUCT ATTRIBUTES

• 3X more hemagglutinin antigen (HA) versus a standard-dose inactivated influenza vaccine

• Made with recombinant DNA technology:
  - Eliminates the need to grow influenza virus
  - Ensures HA cannot experience adaptations or mutations that could reduce vaccine effectiveness

FLUBLOK QUADRIVALENT HAS BEEN PROVEN TO PREVENT MORE INFLUENZA IN ADULTS 50+
compared with a standard-dose quadrivalent inactivated influenza vaccine

ACCORDING TO RESULTS FROM A RANDOMIZED CONTROLLED TRIAL PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE:

PRIMARY ENDPOINT

30% BETTER PROTECTION FROM INFLUENZA
due to any PCR\(^1\) confirmed strain

Secondary Endpoint Definition: The study was culture-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

SECONDARY ENDPOINT

43% BETTER PROTECTION FROM INFLUENZA
due to any culture-confirmed strain

Primary Endpoint Definition: The study was PCR-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

SAFETY IN ADULTS 50+

In this randomized controlled trial, the most common local and systemic adverse reactions to Flublok Quadrivalent include pain at the injection site, headache, and fatigue.

Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.

SELECT IMPORTANT SAFETY INFORMATION

Flublok Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after previous dose of the vaccine.

Please click to see full Important Safety Information.

Please click to see full Prescribing Information for Flublok Quadrivalent.

Flublok®
QUADRIVALENT
Influenza Vaccine

PRODUCT SNAPSHOT

NATIONAL DRUG CODE
Carton (49281-720-10)¹
Unit (49281-720-88)¹

CPT CODE
90682²

PRODUCT PRESENTATION
- Single-dose, 0.5-mL prefilled syringe³
- 10 syringes per carton³
- For intramuscular injection only³

SELECT IMPORTANT SAFETY INFORMATION
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Please click to see full Important Safety Information.
Please click to see full Prescribing Information for Flublok Quadrivalent.

**INDICATION**

Fluzone Quadrivalent is a vaccine indicated for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent is approved for use in persons 6 months of age and older.

**SELECT IMPORTANT SAFETY INFORMATION**

Fluzone Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine.

Please click to see full Important Safety Information. Please click to see full Prescribing Information for Fluzone Quadrivalent.

**REFERENCES**


<table>
<thead>
<tr>
<th>AGE</th>
<th>VACCINATION STATUS</th>
<th>DOSE</th>
<th>SCHEDULE</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months through 35 months</td>
<td>Not previously vaccinated with influenza vaccine or unknown vaccination history</td>
<td>Two doses, either 0.25-mL or 0.5-mL.</td>
<td>Administer at least 4 weeks apart</td>
</tr>
<tr>
<td></td>
<td>Previously vaccinated with influenza vaccine as recommended by ACIP</td>
<td>One or two doses.</td>
<td>If two doses, administer at least 4 weeks apart</td>
</tr>
<tr>
<td>36 months through 8 years</td>
<td>Not previously vaccinated with influenza vaccine or unknown vaccination history</td>
<td>Two 0.5-mL doses</td>
<td>Administer at least 4 weeks apart</td>
</tr>
<tr>
<td></td>
<td>Previously vaccinated with influenza vaccine as recommended by ACIP</td>
<td>One or two 0.5-mL doses</td>
<td>If two doses, administer at least 4 weeks apart</td>
</tr>
<tr>
<td>9 years and older</td>
<td></td>
<td>One 0.5-mL dose</td>
<td></td>
</tr>
</tbody>
</table>
IMPORTANT SAFETY INFORMATION FOR FLUZONE® QUADRIVALENT (INFLUENZA VACCINE), FLUBLOK® QUADRIVALENT (INFLUENZA VACCINE), AND FLUZONE® HIGH-DOSE QUADRIVALENT (INFLUENZA VACCINE)

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, malaise, and malaise.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.

Before administration, please see the full Prescribing Information for Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent.

To order Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent, call 1-800-VACCINE (1-800-822-2463) or contact your Sanofi Pasteur Vaccine Specialist.

Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent are manufactured and distributed by Sanofi Pasteur Inc.
Fluzone High-Dose Quadrivalent (CPT® code 9066A) is a covered benefit under Medicare Part B.
Fluzone Quadrivalent (CPT® code 90686, 90688) is a covered benefit under Medicare Part B.

Flublok Quadrivalent is manufactured by Protein Sciences Corporation, a Sanofi company, and distributed by Sanofi Pasteur Inc.
Flublok Quadrivalent (CPT® code 90682) is a covered benefit under Medicare Part B.

a CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.